Migraine With Aura
83
13
15
41
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
12 trials with published results (14%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.4%
7 terminated out of 83 trials
85.4%
-1.1% vs benchmark
19%
16 trials in Phase 3/4
29%
12 of 41 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 41 completed trials
Clinical Trials (83)
Trial Designs for Evaluating Migraine Treatment
Mind Body Balance for Pediatric Migraine
Responding With Evidence and Access for Childhood Headaches
Neurogenetic And Hemodynamic Of Migraine Aura And Pfo
The Sequestration of Holistic Stress Management Techniques for Adults
App-Based Migraine Treatment: The Health enSuite Study
Gepant treAtments: EffectIveNess and tolERability (GAINER)
Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
Ditan Acute tReatments: Effectiveness and Tolerability (DART)
RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment
Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38
Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura
Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine
Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room
Migraine With and Without Aura Characteristics and Response to Remote Electrical Neuromodulation (REN) Treatment
Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide
Healthy Living Partnerships for Veterans With Migraine
Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine
PArtial REbreathing for Migraine With Aura 1
Molecular Phenotyping of Migraine Patients According to Sex and Age Through CGRP Quantification